Phaseline

Targets › SELENOK

SELENOK (Selenoprotein K): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Apr 2027.

Required for Ca(2+) flux in immune cells and plays a role in T-cell proliferation and in T-cell and neutrophil migration (By similarity). Involved in endoplasmic reticulum-associated degradation (ERAD) of soluble glycosylated proteins. (UniProt, Q9Y6D0)

Open in Phaseline: the race on SELENOK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
First Affiliated Hospital of Chongqing Medical Universityselenium yeast supplementation
selenium cofactor for selenoprotein synthesis
SELENOP, SELENOK, SELENOW, SELENOFPhase 2Depression - Major Depressive DisorderApr 2027

Conditions

Depression - Major Depressive Disorder (1)

Modalities

small molecule (1)

Companies

First Affiliated Hospital of Chongqing Medical University (1)

Related targets

SELENOP (1) SELENOW (1) SELENOF (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.